Ketogenic dietary therapy for Infantile Spasms

Written by:
Elizabeth Neal MSc PhD RD
Research Dietitian, Matthew’s Friends Clinics
Honorary Research Associate, UCL – Institute of Child Health

Infantile spasms, also known as West syndrome, was first reported in 1841 and affects approximately 1 in 2000 infants (1). It typically presents within the first year of life as spasm-type seizures and an EEG abnormality known as hypsarrhythmia; neuro-developmental delay is frequently seen from a young age. In approximately two thirds of affected infants, the syndrome will be associated with a detectable underlying neurological abnormality (2) and many cases of infantile spasms will progress into another epilepsy syndrome.

First-line treatment options for infantile spasms are adrenocorticotropin hormone (ACTH), oral prednisolone or vigabatrin; the latter being particularly effective at treating spasms associated with tuberous sclerosis (1, 2). These treatments will successfully control seizures in many cases but have significant side effects that limit their duration of use. Alternative anti-epileptic drugs (AEDs) are often used if first-line treatments are unsuccessful, however with more limited success. Continued intractable seizure activity in an infant will impact on long-term cognitive and behavioural outcomes, with considerable cost implications for health services due to need for regular clinical review, hospital treatment, medications and support of other therapies. All other treatment options for this syndrome should therefore be explored as early as possible.

The ketogenic diet (KD) is a high fat, restricted carbohydrate regime that has been used since the 1920s; KD efficacy in epilepsy has been demonstrated in many studies including randomised controlled trials in children (3,4) with a trial in infants currently in progress (5). Retrospective studies have shown this diet to be an effective and welltolerated treatment for infantile spasms (6, 7, 8, 9), with one study reporting significant spasm improvements and less side effects when KD was used as an alternative first-line therapy to ACTH (10). Prospective studies also demonstrate KD efficacy in infantile spasms unresponsive to first line treatments. In a study of 104 infants, 64% had over 50% improvement in spasms after 6 months on KD, 29 of whom became seizure free (11). Another study reported 13 of 17 infants had over 50% seizure reduction after one month on KD, of whom 6 became seizure free, increasing to 11 after 3 months (12). Similar results were found in a further group of 20 infants of whom 70% had over 50% seizure reduction after 3 months on the diet (13). However, one study of 22 children has questioned whether complete seizure response to KD can be achieved in highly refractive spasms (14).

A trial comparing efficacy and tolerability of KD with standard high-dose ACTH treatment for infantile spasms followed 101 infants (32 in a randomised trial and 69 in a parallel cohort) including those with and without prior vigabatrin treatment. Results showed similar electroclinical remission in ACTH and KD groups after 28 days but better tolerance in the KD group. The authors concluded that without prior vigabatrin treatment, ACTH should be first choice to achieve short-term seizure remission, however with prior vigabatrin, the KD was as effective as ACTH with lower long-term relapse rate (15). A systematic review of KD efficacy in infantile spasms included 13 observational studies with results supporting benefit of the diet: out of a total 341 patients, a median of 65% experienced over 50% spasm reduction and 35% were spasm-free, although this fell to 10% with longer follow up data (16).

International consensus recommendations suggest that the KD should be strongly considered in a child with epilepsy who has failed two or three AEDs and may be particularly beneficial in certain epilepsy syndromes such as infantile spasms (17). Updated UK NICE guidelines on management of the epilepsies also recommend children with epilepsy whose seizures have not responded to appropriate AEDs are referred to a tertiary paediatric epilepsy specialist for consideration of the KD (CG137, nice.org.uk). Practical guidelines and recommendations for specific KD use in infants have also been published (18).

Early KD use in infants is recommended: a review of outcomes in 115 children with a range of epilepsy syndromes, over half with infantile spasms, found significantly more infants under 18 months of age achieved seizure freedom when compared to those over 18 months, this difference was even greater when infants under 9 months of age were examined separately (9). The KD can be initiated in infants maintained on breast milk (19) and, with careful screening, used safely in a neonatal intensive care setting (20). The most common reported side effects of the diet are gastro-intestinal disturbances especially constipation and reflux, altered lipid levels, renal stones and acidosis; most complications are transient and controlled with diet adjustment and monitoring (18). Short-term KD trials are unlikely to have any adverse effect on linear growth (21), however this may be more of a problem with longer-term use

We therefore propose that infants with infantile spasms who have failed appropriate first-line treatment options are funded for an initial assessment of suitability for the KD. Evaluation after two or three months on diet is suggested to allow adequate assessment of benefit and appropriate fine-tuning of the dietary prescription to individual needs; earlier assessment after one month may be needed in infants on KD as first, second or third line treatment in view of the risks of uncontrolled seizures (18). Although it is often suggested that children with epilepsy who are benefiting from KD continue this for at least two years, duration of treatment could be shorter in patients with infantile spasms who become seizure-free; one study reported no adverse effect on seizure outcomes and less risk of growth disturbances when diet treatment was tapered down after 8 months (22).

References

    1. Kossoff EH (2010) Infantile spasms.. Neurologist 16(2):69-75.
    2. Hancock EC, Osborne JP, Edwards SW (2008) Treatment of infantile spasms. Cochrane Database Syst Rev. CD001770.
    3. Neal EG, Chaffe HM, Schwartz R, et al (2008) The ketogenic diet in the treatment of epilepsy: a randomised controlled trial. Lancet Neurol. 7:500-6.
    4. Lambrechts DA, de Kinderen RJ, Vles JS, et al (2017) A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy. Acta Neurol Scand. 135(2):231-9.
    5. Titre-Johnson S, Schoeler N, Eltze C et al (2017) Ketogenic diet in the treatment of epilepsy in children under the age of 2 years: study protocol for a randomised controlled trial. Trials. 18(1):195.
    6. Kossoff EH, Pyzik PL, McGrogan JR, et al (2002) Efficacy of the ketogenic diet for infantile spasms. Pediatrics 109(5):780-3.
    7. Rubenstein JE, Kossoff EH, Pyzik PL, et al (2005) Experience in the use of the ketogenic diet as early therapy. J Child Neurol. 20(1):31-4
    8. Eun SH, Kang HC, Kim DW, Kim HD (2006). Ketogenic diet for treatment of infantile spasms. Brain Dev. 28(9):566-71.
    9. Dressler A, Trimmel-Schwahofer P, Reithofer E, et al (2015) The ketogenic diet in infants–Advantages of early use. Epilepsy Res. 116:53-8.
    10. Kossoff EH, Hedderick EF, Turner Z, Freeman JM (2008) A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 49(9):1504-9.
    11. Hong AM, Turner Z, Hamdy RF, Kossoff EH (2010) Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia 51(8):1403-7.
    12. Pires ME, Ilea A, Bourel E, et al (2013) Ketogenic diet for infantile spasms refractory to first-line treatments: an open prospective study. Epilepsy Res. 105(1-2):189-94.
    13. Kayyali HR, Gustafson M, Myers T, et al (2014) Ketogenic diet efficacy in the treatment of intractable epileptic spasms. Pediatr Neurol. 50(3):224-7.
    14. Hussain SA, Shin JH, Shih EJ, et al (2016) Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic spasms. Seizure. 35:59-64.
    15. Dressler A, Benninger F, Trimmel-Schwahofer P, et al (2019) Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial. Epilepsia. 60(3):441-51.
    16. Prezioso G, Carlone G, Zaccara G, Verrotti A (2018) Efficacy of ketogenic diet for infantile spasms: A systematic review. Acta Neurol Scand. 137(1):4-11.
    17. Kossoff EH, Zupec-Kania BA, Amark PE, et al (2009). Optimal clinical management of children receiving the ketogenic diet: recommendations of the international ketogenic diet study group. Epilepsia 50:304-17.
    18. Van der Louw E, van den Hurk D, Neal E (2016) Ketogenic diet guidelines for infants with refractory epilepsy. Eur J Paediatr Neurol. 20(6):798-809.
    19. Le Pichon JB, Thompson L, Gustafson M, Abdelmoity A (2019) Initiating the ketogenic diet in infants with treatment refractory epilepsy while maintaining a breast milk diet. Seizure 69:41-43.
    20. Thompson L, Fecske E, Salim M, Hall A (2017) Use of the ketogenic diet in the neonatal intensive care unit-Safety and tolerability. Epilepsia.58(2):e36-e39.
    21. Numis AL, Yellen MB, Chu-Shore CJ, et al (2011) The relationship of ketosis and growth to the efficacy of the ketogenic diet in infantile spasms. Epilepsy Res. 96(1-2):172-5
    22. Kang HC, Lee YJ, Lee JS, et al (2011) Comparison of short- versus long-term ketogenic diet for intractable infantile spasms. Epilepsia 52(4):781-7.

> Download a PDF Version of This